Summary of Key Points Core Viewpoint The announcement details the implementation of the 2023 Restricted Stock Incentive Plan by Guangzhou Maipu Medical Technology Co., Ltd., highlighting the conditions for the first vesting period and the allocation of restricted stocks to eligible participants. Group 1: Incentive Plan Overview - The total number of restricted stocks to be granted under the incentive plan is 1.868 million shares, accounting for approximately 2.83% of the company's total share capital as of the announcement date [2][3] - The initial grant consists of 1.768 million shares, representing about 2.68% of the total share capital, while the reserved grant includes 100,000 shares, or 0.15% of the total [2][3] - The plan includes 49 eligible participants, including directors, senior management, and key technical and business personnel, excluding independent directors and foreign employees [2][3] Group 2: Vesting Conditions - The vesting period for the restricted stocks is set for a maximum of 60 months from the date of the first grant [3][4] - The first vesting period will begin 12 months after the grant date, with stocks vesting in stages based on performance conditions [4][5] - The performance conditions include company-level revenue growth targets for the years 2023 to 2025, with specific percentage targets set for each year [7][8] Group 3: Performance Assessment - The company-level performance targets for the first vesting period require a revenue growth rate of 12% for 2023, 45% for 2024, and 90% for 2025 [7][8] - Individual performance assessments will also be conducted, with results categorized into five levels (S, A, B, C, D) affecting the actual number of stocks vested [7][8] - If the performance targets are not met, the corresponding restricted stocks will be canceled and will not carry over to the next year [8][9] Group 4: Legal and Regulatory Compliance - The plan has undergone necessary approvals and has been deemed compliant with relevant laws and regulations, including the Company Law and Securities Law [21][22] - The company has adjusted the grant price of the restricted stocks from 20.80 RMB to 20.40 RMB per share due to capital adjustments [19][20] - The board has confirmed that the vesting conditions for the reserved grant have been met, allowing for the processing of stock vesting for eligible participants [18][21]
迈普医学: 关于2023年限制性股票激励计划预留授予部分第一个归属期归属条件成就的公告